# CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

> **NCT01664910** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 27 (actual)

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm

## Interventions

- **PROCEDURE:** Allogeneic Bone Marrow Transplantation
- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **BIOLOGICAL:** Anti-Thymocyte Globulin
- **DRUG:** Bendamustine Hydrochloride
- **DRUG:** Fludarabine Phosphate
- **BIOLOGICAL:** Inotuzumab Ozogamicin
- **DRUG:** Methotrexate
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation
- **BIOLOGICAL:** Rituximab
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT01664910
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-29
- **Primary completion:** 2023-06-28
- **Final completion:** 2023-06-28
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2024-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01664910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01664910, "CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01664910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*